Skip to content

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Investor Presentation 16 May 2016

May 16, 2016

Download the Investor Presentation available on Google Drive and ASX.

Categories ASX Announcements

Post navigation

InvitroCue Announces Malaria Initiative

Investor Presentation (Mandarin)

Search for:

Recent Posts

Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
Operational Updates – February 2024
Operational Updates – October 2023
Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com

SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings